References
- Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, et al (1991). Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol, 9, 818-26.
- Ataergin S, Ozet A, Arpaci F, et al (2007). Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center. Indian J Cancer, 44, 6-11. https://doi.org/10.4103/0019-509X.31161
- Beyer J, Albers P, Altena R, et al (2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 24, 878-88. https://doi.org/10.1093/annonc/mds579
- Daugaard G, Skoneczna I, Aass N, et al (2011). A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol, 22, 1054-61. https://doi.org/10.1093/annonc/mdq575
- de Wit R, Stoter G, Sleijfer DT, et al (1998). Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer, 78, 828-32. https://doi.org/10.1038/bjc.1998.587
- Devesa SS, Blot WJ, Stone BJ, et al (1995). Recent cancer trends in the United States. J Natl Cancer Inst, 87, 175-82. https://doi.org/10.1093/jnci/87.3.175
- Droz JP, Kramar A, Biron P, et al (2007). Genito-Urinary Group of the French Federation of Cancer. Failure of high-dose cyclophosphamide and etoposide combined with doubledose cisplatin and bone marrow support in patients with highvolume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol, 51, 739-746. https://doi.org/10.1016/j.eururo.2006.10.035
- Droz JP, Kramar A, Ghosn M, et al (1988). Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer, 62, 564-8. https://doi.org/10.1002/1097-0142(19880801)62:3<564::AID-CNCR2820620321>3.0.CO;2-A
- Edge SB BD, Compton CC (2010). AJCC Cancer Staging Manual. New York, NY: Springer.
- Einhorn LH, Donohue J.(1977). Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med, 87, 293-8. https://doi.org/10.7326/0003-4819-87-3-293
- Hanson PR, Belitsky P, Millard OH, Lannon SG. (1993). Prognostic factors in metastatic nonseminomatous germ cell tumours. Can J Surg, 36, 537-40.
- Hartmann JT, Nichols CR, Droz JP, et al (2002). Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. [Multicenter Study]. Ann Oncol, 13, 1017-28. https://doi.org/10.1093/annonc/mdf176
- Horwich A, Sleijfer DT, Fossa SD, et al (1997). Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in goodprognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Tria. J Clin Oncol, 15, 1844-52.
- International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group (1997). J Clin Oncol, 15, 594-603.
- Javadpour N, Young JD, (1986). Prognostic factors in nonseminomatous testicular cancer. J Urol, 135, 497-499.
- Kamba T, Kamoto T, Okubo K, et al (2010). Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol, 17, 980-7. https://doi.org/10.1111/j.1442-2042.2010.02645.x
- Kaye SB, Mead GM, Fossa S, et al (1998). Intensive inductionsequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol, 16, 692-701.
- Keskin S, Ekenel M, Basaran M, Bavbek S (2012). Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy. [Comparative Study]. Am J Clin Oncol, 35, 369-72. https://doi.org/10.1097/COC.0b013e3182155370
- Kollmannsberger C, Nichols C, Meisner C, et al (2000). Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 11, 1115-20. https://doi.org/10.1023/A:1008333229936
- Krege S, Beyer J, Souchon R, et al (2008). European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol, 53, 497-513. https://doi.org/10.1016/j.eururo.2007.12.025
- Mazumdar M, Bajorin DF, Bacik J, et al (2001). Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol, 19, 2534-41.
- Motzer RJ, Agarwal N, Beard C, et al (2012). National Comprehensive Cancer, N. Testicular cancer. [Practice Guideline]. J Natl Compr Canc Netw, 10, 502-35.
- Motzer RJ, Nichols CJ, Margolin KA, et al (2007). Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 25, 247-56. https://doi.org/10.1200/JCO.2005.05.4528
- Nichols CR, Williams SD, Loehrer PJ, et al (1991). Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol, 9, 1163-72.
- Pohar KS, Rabbani F, Bosl GJ, et al (2003). Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol, 170, 1155-8. https://doi.org/10.1097/01.ju.0000087796.63505.70
- Schmoll HJ, Beyer J (1998). Prognostic factors in metastatic germ cell tumors. [Review]. Semin Oncol, 25, 174-85.
- Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Stoter G, Sylvester R, Sleijfer DT, et al (1987). Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res, 47, 2714-8.
- Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, et al (2000). Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. J Clin Oncol, 18, 358-62.
- van Dijk MR, Steyerberg EW, Stenning SP, Dusseldorp E, Habbema JD (2004). Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer, 90, 1176-83. https://doi.org/10.1038/sj.bjc.6601665
- Vogt AP, Chen Z, Osunkoya AO. (2010). Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding? Hum Pathol, 41, 1339-44. https://doi.org/10.1016/j.humpath.2010.03.005
- Warde P, Specht L, Horwich A, et al (2002). Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. [Meta-Analysis]. J Clin Oncol, 20, 4448-52. https://doi.org/10.1200/JCO.2002.01.038
- Williams SB, Kacker R, Winston D, et al (2011). Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer. J Urol, 186, 2245-8. https://doi.org/10.1016/j.juro.2011.07.101
- Williams SD, Birch R, Einhorn LH, et al (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med, 316, 1435-40. https://doi.org/10.1056/NEJM198706043162302
Cited by
- Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3525
- Knowledge, Attitude and Practices of Technicians Working at Hospitals Towards Testicular Cancer and Self-examination of Testicles in Turkey vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10095
- T Cells after Allogeneic Hematopoietic Stem Cell Transplantation and its Correlation with Invasive Fungal Infection in Patients with Hematological Malignancies vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3137